All In Biotech

Drug Trial Radar · NCT01518166

Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH

A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin, Griseofulvin and Digoxin, and Liraglutide's Potential Influence on Intragastric pH

Last checked: Nov 19, 2026Latest source record: Jan 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

May 2006

Primary completion

Apr 2007

Study completion Apr 2007

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 25, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®), griseofulvin and digoxin (Lanoxin®).

Conditions

  • Diabetes
  • Healthy

Interventions

  • liraglutideDrug

    Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3

  • placeboDrug

    Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively

  • atorvastatinDrug

    One single dose of 40 mg. Tablet

  • lisinoprilDrug

    One single dose of 20 mg. Tablet

  • griseofulvinDrug

    One single dose of 500 mg. Tablet

  • digoxinDrug

    One single dose of 1 mg. Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the curve of atorvastatin
  2. Area under the curve of lisinopril
  3. Area under the curve of griseofulvin
  4. Area under the curve of digoxin

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.